Inject less. 
Strive for more.

Inject less. Strive for more.

Elucirem™ is the next generation GBCA from Guerbet, designed to reveal high-quality images at half the conventional gadolinium dose1


Welcome to a new world of low dose gadolinium

1 Reducingdose

Reducing the dose of gadolinium with Elucirem™

With a high consumption of GBCAs worldwide and recommendations to reduce the dose of gadolinium, Elucirem™ uses 50% less gadolinium with benefits that go beyond image quality1-9

Half the dose

2 Design

Ingeniously designed

The unique structure of gadopiclenol has 2 water molecule exchange sites designed to maximize the efficiency of gadolinium (Gd) so only half the conventional dose is needed10

Innovative mechanism of action

3 Diagnostic

Diagnostic confidence

With its high relaxivity, Elucirem™ is designed to deliver high- quality CNS and body lesion visualization giving you the diagnostic confidence* you would expect but at half the conventional gadolinium dose1,7,8,10

*Diagnostic confidence was a secondary criterion. 

Clinical efficacy

4 Comparaison

High kinetic stability compared to other GBCAs

Elucirem™ (gadopiclenol) has a high kinetic stability with a comparable safety profile to gadobutrol1,7,8,10

Clinical safety

5 Dosing

Straightforward dosing

For both adults and children (aged 2 years and over), Elucirem™ has the same weight-based dosing1

Dosing and administration

Elucirem™ is the next generation GBCA that is exclusively manufactured by Guerbet1

GBCA: Gadolinium-Based Contrast Agent
MRI: Magnetic Resonance Imaging


1. Elucirem Summary of Product Characteristics. 2023.
2. Health at a Glance 2019: OECD Indicators. Accessed November 2023.
3. Health at a Glance 2021: OECD Indicators. Accessed November 2023.
4. Runge VM. Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus. Invest Radiol. 2016;51(5):273-279
5. PRAC confirms restrictions on the use of linear gadolinium agents. Benefit-risk balance of certain linear gadolinium agents no longer favourable. European Medicines Agency, 2017.
6. European Society of Urogenital Radiology. ESUR Guidelines on Contrast Agents. 2022/03/ESUR-Guidelines-10_0-Final-Version.pdf. Accessed March 2023.
7. Loevner LA, Kolumban B, Hutóczki G, et al. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial. Invest Radiol. 2023 May 1;58(5):307-313.
8. Kuhl C, Csőszi T, Piskorski W, et al. Efficacy and safety of half-dose gadopiclenol versus full-dose gadobutrol for contrast-enhanced body MRI. Radiology. 2023 Jul;308(1):e222612.
9. Brünjes R, Hofmann T. Anthropogenic gadolinium in freshwater and drinking water systems. Water Res. 2020;182:115966.
10. Robic C, Port M, Rousseaux O, et al. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Invest Radiol. 2019 Aug;54(8):475-484.

Click here for the SmPC. For more information, please refer to your local product information